Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Clinicians and researchers are rapidly adapting to working in the midst of a pandemic. Herein, we share our initial thoughts of the consequences of COVID-19 for the oncology community.
Dramatic reductions in drug costs in 2020 are unlikely, although early signs suggest that the issue of unsustainable drug pricing is beginning to attract the attentions of policymakers.
Phase I trials form the foundations of evidence-based oncology. Here, we explore the ethical controversies surrounding how participation in such trials should be presented to patients.
An increasing number of studies suggest that artificial intelligence could revolutionize medicine. In oncology, we are only beginning to fully understand the practical implications.
The negative results of the ANNOUNCE trial, resulting in withdrawal of olaratumab from the market, illustrate the difficulties in balancing access to novel therapies with the need for proven benefit.